Endovalve Begins Preclinical Animal Testing of its Mitral-Valve Replacement System, Which Demonstrates Key Feasibility Criteria
SAN FRANCISCO--(BUSINESS WIRE)--Endovalve, Inc., a cardiovascular device company developing the first percutaneous valve-replacement system to treat mitral regurgitation, today announced that it has developed a to-scale functional model of the valve and anchor design, successfully demonstrated important feasibility criteria and begun preclinical animal testing.